Candel Therapeutics News

Candel Therapeutics | 8-K: Current report

Apr 25 08:34 ET

Candel Therapeutics | 10-K/A: Annual report (Amendment)

Apr 25 07:35 ET

Candel Therapeutics | 8-K: Current report

Apr 11 09:04 ET

Candel Therapeutics | 8-K: Current report

Apr 9 08:34 ET

Candel Therapeutics | 8-K: Current report

Apr 4 08:35 ET

Candel Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

Mar 28 08:19 ET

Candel Therapeutics | 10-K: Annual report

Mar 28 08:05 ET

Candel Therapeutics | 8-K: Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights

Mar 28 07:49 ET

Candel Therapeutics | 8-K: Current report

Mar 6 08:03 ET

Candel Therapeutics | 424B5: Prospectus

Feb 13 09:04 ET

Candel Therapeutics | 8-K: Current report

Feb 13 07:49 ET

Candel Therapeutics | 3: Initial statement of beneficial ownership of securities-Officer Schoch Charles

Jan 19 00:00 ET

Candel Therapeutics | 8-K: Current report

Jan 12 00:00 ET

Candel Therapeutics | 8-K: Current report

Jan 3 00:00 ET

Candel Therapeutics | 8-K: Current report

Dec 14, 2023 18:33 ET

Candel Therapeutics | 8-K: Current report

Dec 12, 2023 08:30 ET

Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Technology Officer Tyagarajan Seshu

Nov 30, 2023 17:00 ET

Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Chief Executive Officer Tak Paul Peter

Nov 30, 2023 17:00 ET

Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Nichols William Garrett

Nov 30, 2023 17:00 ET

Candel Therapeutics | 4: Statement of changes in beneficial ownership of securities-Officer Barone Francesca

Nov 30, 2023 17:00 ET